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A Novel Locus for Generalized Epilepsy With Febrile
Seizures Plus in French Families
Ste´phanie Baulac, PhD; Isabelle Gourfinkel-An, MD, PhD; Philippe Couarch, BS; Christel Depienne, PhD;
Anna Kaminska, MD; Olivier Dulac, MD; Michel Baulac, MD; Eric LeGuern, MD, PhD; Rima Nabbout, MD, PhD
Background: Generalized epilepsy with febrile sei-
zures plus (GEFS) is a familial autosomal dominant en-
tity characterized by the association of febrile and afe-
brile seizures. Mutations in 3 genes—the sodium channel
1 subunit gene (SCN1A), the sodium channel 1 sub-
unit gene (SCN1B), and the 2 GABA receptor subunit
gene (GABRG2)—and linkage to 2 other loci on 2p24 and
21q22 have been identified in families with GEFS, in-
dicating genetic heterogeneity.
Objectives: To localize by means of linkage analysis a
new gene for GEFS in a large family with 11 affected
members and to test the new locus in 4 additional fami-
lies with GEFS.
Design: Family-based linkage analysis.
Setting: University hospital.
Patients: Five French families with GEFS and at least 7
availableaffectedmemberswithautosomaldominant trans-
mission.All thepatientshad febrile seizures and/orafebrile
generalized tonic-clonic seizures or absence epilepsy.
Main Outcome Measures: We analyzed 380 micro-
satellite markers and conducted linkage analysis.
Results: In the largest family, a 10-cM-density genome-
wide scan revealed linkage to a 13-Mb (megabase) in-
terval on chromosome 8p23-p21 with a maximum pair-
wise logarithm of odds (LOD) score of 3.00 (at=0) for
markersD8S351 andD8S550 and a multipoint LOD score
of 3.23. A second family with GEFS was also possibly
linked to chromosome 8p23-p21 and the region was nar-
rowed to a 7.3-Mb candidate interval, flanked by mark-
ers D8S1706 and D8S549. We have not, so far, identi-
fied mutations in the coding exons of 6 candidate genes
(MTMR9,MTMR7,CTSB, SGCZ, SG223, andATP6V1B2)
located in the genetic interval.
Conclusions: We report a sixth locus for GEFS on chro-
mosome 8p23-p21. Because no ion channel genes are lo-
cated in this interval, identification of the responsible gene
will probably uncover a new mechanism of pathogen-
esis for GEFS.
Arch Neurol. 2008;65(7):943-951
G ENERALIZED EPILEPSYwith febrile seizures plus(GEFS) is a familialcondition in which pa-tients have febrile sei-
zures (FSs) variably associated with epi-
lepsy.1 Febrile seizures are the most
common convulsive event in humans, af-
fecting 2% to 5% of children.2 They are trig-
gered by fever and typically occur be-
tween ages 6 months and 6 years; the
outcome is benign. In families with GEFS,
patients present with either FSs or FS. Pa-
tients with the FS phenotype have FSs
that persist beyond the classic age of 6
years, and they may be particularly nu-
merous or may co-occur with afebrile sei-
zures.2 Variable types of afebrile seizures
are observed in patients. Most often, these
are generalized seizures (tonic-clonic,
myoclonic, atonic, tonic, and absence sei-
zures), but hemiconvulsive, temporal, and
frontal seizures have also been ob-
served.3-5 Afebrile seizures may begin dur-
ing childhood in association with FSs, af-
ter a variable seizure-free period, or in
patients without a history of FSs. The dis-
ease course and the response to antiepi-
leptic drugs are also highly variable within
families, but seizures are most often con-
trolled by classic antiepileptic drug treat-
ment. When available, neuroimaging find-
ings in epileptic patients are normal.
The GEFS context is inherited as an
autosomal dominant trait with incom-
plete penetrance. It is genetically hetero-
geneous. The voltage-gated sodium chan-
nel 1 subunit gene (SCN1B [OMIM
600235]) (19q13.1),6 the sodium chan-
nel 1 subunit gene (SCN1A [OMIM
182389]) (2q21-q33),7 and the 2 GABA
receptor subunit gene (GABRG2 [OMIM
137164]) (5q34)8,9 have been implicated
in GEFS. More recently, 2 new GEFS
loci on 2p24 and 21q22 were reported, but
the genes remain to be identified.10,11 In ad-
dition, 3 loci for autosomal dominant FSs
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have been reported: febrile convulsions 1 gene (FEB1)
on chromosome 8q13-q21,12 FEB2 on 19p13,13 and FEB5
on 6q22-q24.14
Herein, we ascertained 5 French families with GEFS
without linkage to FS or GEFS loci previously re-
ported. Conclusive linkage to chromosome 8p23-p21 was
obtained in a large multigenerational family, and, in a sec-
ond family, linkage to the same locus was suggested.
METHODS
FAMILIES
Five French families with at least 7 affected members for whom
DNA was available were identified during a national cam-
paign organized by the Association de Recherche sur la Ge´ne´-
tique des Epilepsies and supported by the French Ge´ne´thon
Center. Simplified pedigrees of the families are given in
Figure 1. All members of the families underwent clinical as-
sessment using a detailed questionnaire. Information was also
obtained retrospectively from medical records. Informed con-
sent was obtained from all the participants or from their legal
representatives.
GENOTYPING
Genomic DNA was isolated from blood lymphocytes using stan-
dard procedures. Genome scans for families 15173 and 12402
were performed at the Centre National de Ge´notypage. The set
consisted of 400 fluorescent microsatellite markers (includ-
ing 20 for chromosome X that were not tested because of a male-
to-male transmission in each family) selected from the Ge´ne´-
thon human linkage map that cover the entire human genome
with a resolution of approximately 10 cM. Subsequent mark-
ers used for fine mapping were genotyped as previously re-
ported.4
LINKAGE ANALYSIS
We calculated parametric pairwise logarithm of odds (LOD)
scores using the MLINK program and multipoint LOD scores
using the Allegro program, assuming an autosomal dominant
trait with a disease allele frequency of 0.0001, penetrance of
0.60, equal recombination fractions in males and females, and
equal frequencies for the alleles observed in the families. These
variables were also used to calculate theoretical maximum LOD
scores using the “affected only” method. At-risk individuals I:4
(67 years old), II:8 (40 years old), III:3 (21 years old), and III:6
(11 years old) of family 15173 and at-risk individuals I:2 (60
years old), I:6 (69 years old), II:3 (33 years old), II:5 (40 years
old), and II:6 (38 years old) of family 12402 were clinically nor-
mal and were, thus, considered to be unaffected. All individu-
als who experienced 1 or more FSs or afebrile seizures were
considered to be affected.
SEQUENCING
A mutation search by means of direct sequencing was per-
formed in the coding exons and flanking splice sites of 6 can-
didate genes (MTMR9 [OMIM 606260], MTMR7 [OMIM
603562], CTSB [OMIM 116810], SGCZ [OMIM 608113],
Male
Female
Affected (FSs or ASs)
Unaffected
Deceased
DNA samples available∗ ∗
Family 16923
∗ ∗ ∗ ∗ ∗
∗∗∗∗∗ ∗ ∗
∗ ∗ ∗ ∗ ∗ ∗ ∗
∗ ∗ ∗ ∗ ∗ ∗
Family 17516
∗ ∗








∗ ∗ ∗ ∗ ∗ ∗ ∗
∗ ∗ ∗ ∗ ∗
∗ ∗
∗












∗ ∗ ∗ ∗ ∗ ∗ ∗ ∗
∗ ∗ ∗ ∗
∗
Figure 1. Pedigrees of the 5 families with generalized epilepsy with febrile seizures plus. AS indicates afebrile seizure; FS, febrile seizure.
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SG223, and ATP6V1B2 [OMIM 606939]). The genomic orga-
nization of the candidate genes and the primer sequences were
obtained from the University of California Santa Cruz Web site
(http://genome.ucsc.edu/) and are available on request. Poly-
merase chain reaction products were sequenced on both strands
on an ABI3730 automatic sequencer using the Big Dye Termi-





We identified a 3-generation kindred with 22 family mem-
bers: 11 affected individuals with a history of at least
1 FS, 3 of whom also had afebrile seizures, 2 unaffected
obligate carriers, 5 unaffected individuals, and 5 mar-
ried-in individuals (Table 1 and Figure 2). No blood
sample was available for patient II:7, who experienced
1 FS.
The FSs began at age 8 months to 1.5 years and per-
sisted beyond age 6 years in 4 patients (II:1, 11 years; II:3,
10 years; II:4, 11 years; and III:7, 6.5 years). The num-
ber of FSs was particularly high in 3 patients in genera-
tion II despite the prescription of antiepileptic drugs (20
episodes of FS in patient II:1 and 15 in patient II:3). In
addition, individual II:4 had an association of FSs and
afebrile seizures; he experienced a total of 50 seizures be-
tween ages 1 to 11 years. Two individuals had complex
FSs: II:4 had 1 prolonged FS followed by transitory
hemiplegia at 1 year of age and another prolonged FS with-
out a motor deficit 6 months later, and III:7 had several
FSs lasting more than 30 minutes, 1 of which was fol-
lowed by transitory hemiplegia.
Three individuals (II:1, II:4, and III:5) also had afebrile
seizures. Individual II:1 had 1 generalized tonic-clonic sei-
zure (GTCS) during a period of sleep deprivation and al-
cohol intake and another seizure during treatment with an
antidepressant drug. Interictal electroencephalography
(EEG) showed rare generalized spike waves in this pa-
tient. Individual II:4, after the period (1-11 years) of mix-
ture of FSs and afebrile seizures, was completely seizure-
free until age 40 years, when he had an afebrile GTCS in a
context of stress and sleep deprivation. An EEG was not
available. None of these patients was receiving antiepilep-












Occurrence Pattern No. Interictal EEG
Family 15173
I:2/M/76 1.5 y 4 y 5 Unknown Not app Not app Not app Not app Normal
II:1/M/41 1 y 11 y 20 No 30 y 40 y GTCSs 2a Rare generalized SWs
II:3/F/46 1 y 10 y 15 No Not app Not app Not app Not app NA
II:4/M/47 1 y 11 y 50b Yes 1 y 40 y GTCSs Several NA
II:6/F/49 1 y 1 y 1 No Not app Not app Not app Not app NA
II:7/M/41 1.5 y 1.5 y 1 No Not app Not app Not app Not app NA
III:2/M/16 10 mo 16 mo 3 No Not app Not app Not app Not app NA
III:4/M/19 1 y 1 y 1 No Not app Not app Not app Not app NA
III:5/F/17 1 y 5 y 5 No 15 y 17 y Absences  GTCSs Several Rare generalized SWs
III:7/F/7 1 y 6.5 y 10 Yes Not app Not app Not app Not app NA
III:9/F/11 8 mo 8 mo 1 No Not app Not app Not app Not app NA
Family 12402
I:1/F/59 14 mo 6 y 5 No Not app Not app Not app Not app NA
I:4/M/61 12 mo 6 y 5 Yes 1 y 9 y GTCSs 3 NA
I:8/F/66 18 mo 8 y 10 No Not app Not app Not app Not app NA
II:2/F/37 24 mo 24 mo 1 No 10 y 35 y Absences  GTCSs Several  1 Generalized SWs (3 Hz);
photosensitivity
II:4/F/46 Not app Not app Not app Not app 16 y 18 y Absences  GTCSs Many 1 Generalized SWs (3 Hz);
photosensitivity
II:7/F/43 9 mo 4 y 4 Yes Not app Not app Not app Not app NA
II:8/M/33 12 mo 3 y 3 No Not app Not app Not app Not app NA
I:10/F/died at 14
(cranial trauma)
Not app Not app Not app Not app 7 y Unknown Absences Many NA
I:11/F/died at 50
(unknown)












Abbreviations: EEG, electroencephalogram; GTCS, generalized tonic-clonic seizure; NA, not available; Not app, not applicable; SW, spike wave.
aOne seizure occurred with sleep deprivation and alcohol intake, another during treatment with antidepressant.
bMixture of febrile and afebrile seizures.
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tic drugs when examined. For individual III:5, GTCSs and
absences began during adolescence. Interictal EEG showed
rare generalized spike waves. All affected family members
have had normal psychomotor development, and even in-
dividuals with a high number of or complex FSs have had
good school performance.
Family 12402
In this second 4-generation family, 11 individuals were
affected (data were available for only 10 individuals)
(Table 1 and Figure 3). Four individuals were dead at
the time of this study; DNA was, therefore, available for
only 7 individuals. Six of these 7 patients had FSs, with
ages at onset ranging from 9 to 24 months. All FSs stopped
before or at age 6 years except in 1 patient (I:8) who had
his last FS at age 8 years. He also had the highest num-
ber of episodes (10 FSs). The FSs were simple in 4 pa-
tients, consisting of brief GTCS, but in 2 patients (I:4 and
II:7) they lasted up to 15 to 20 minutes (complex FSs).
Two patients (II:2 and II:4) also had absence epilepsy,
with late childhood onset and a 3-Hz spike wave pattern
recorded by means of EEG. In addition, in patient I:4, afe-
brile GTCS occurred during the same period as FSs and
stopped by age 9 years. Three family members who died
before the study had epilepsy with no reported FSs: the first
had absence epilepsy (I:10), and the other 2 had temporal
lobe seizures beginning in adolescence (I:11 and II:9). The
cause of death was undetermined for patient I:11. Ab-
sence epilepsy in this family was of late onset (I:10, 7 years;
II:2, 10 years; and II:4, 16 years) and highly photosensi-
tive. No lesions were observed by means of magnetic reso-
nance imaging (MRI) in patients with temporal lobe epi-
lepsy. Psychomotor development was normal in all affected
family members. Performance in school of patient II:2 de-
clined from age 12 years; she was oriented toward a pro-
fession at age 16 years.
Families 16923, 17516, and 15635
In family 16923 (8 affected individuals), FSs were simple,
infrequent (n=1-4), and stopped before age 6 years. Two
patients had afebrile GTCS at ages 3 and 6 years and were
fully controlled with antiepileptic drug monotherapy.
In family 17516, 10 patients had FSs, which were
simple, recurred 2 to 3 times except in 1 patient (n=8),
and stopped before 6 years of age. Three patients had afe-

















































































































































































































































































































































































































































































































































































































































































































































































Figure 2. Haplotype reconstruction for chromosome 8p23-p21 markers in family 15173. Microsatellite and VNTR markers are ordered from telomere to
centromere according to the University of California Santa Cruz genome map. The haplotype segregating with the disease is boxed. Observed recombinations are
indicated by arrows. Mb indicates megabase.
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currence unknown) but recurred 3 times in the other 2
patients, at ages 4 and 9 years. Seizures in these 2 pa-
tients were fully controlled by antiepileptic drug
monotherapy.
In family 15635, 9 patients had simple FSs that stopped
before age 6 years. One patient had 1 afebrile GTCS at
12 years of age, and 2 half-brothers developed rare par-
tial seizures in adolescence. Their brain MRIs were nor-
mal. They were not pharmacoresistant at the time of this
study and were 17 and 20 years of age. Their mother had
isolated FSs. All affected members of these 3 families had
normal psychomotor development.
LINKAGE ANALYSIS
Exclusion of Known FS and GEFS Loci
We first examined whether any of the 5 families pre-
sented linkage to previously reported loci for GEFS and
FS. Negative pairwise LOD scores were obtained in all 5
families, excluding the following loci as the cause of the
disease: 19q13 (SCN1B), 2q24 (SCN1A), 5q34 (GABRG2),
2p24 (GEFS4), 21q32 (GEFS5), 8q13-21 (FEB1),
19p13 (FEB2), and 6q22-24 (FEB5) (data not shown).
We then calculated the maximal theoretical pairwise
LOD scores to determine which families were suffi-
ciently informative to map a new gene. Using the af-
fected only method, at=0.0, family 15173 (DNA avail-
able for 10 affected members) had a Zmax of 3.06, family
12402 (DNA available for 7 affected members) had a Zmax
of 1.7, family 16923 (DNA available for 8 affected mem-
bers) had a Zmax of 2.7, family 15635 (DNA available for
7 affected members) had a Zmax of 1.8, and family 17516
(DNA available for 7 affected members) had a Zmax of 1.8.
Genomewide Scan in Family 15173
A genome scan of all autosomes was conducted with 380
microsatellite markers in family 15173, the only family
in which the theoretical maximal pairwise LOD score
reached the threshold value of 3.00 in linkage analyses.
Calculation of pairwise LOD scores revealed 20 of 380
noninformative markers, which were excluded by means
of haplotype reconstruction (data not shown). In addi-
tion, positive pairwise LOD scores were obtained for 6
markers (D10S208,D15S130,D16S423, andD18S61 and
the 2 adjacent markers D8S351 and D8S550). Fine map-
ping with additional markers (D10S183, D10S199,
D15S531,D15S207,D16S3030,D16S3134,D18S1125, and
D18S386) excluded the regions on chromosomes 10, 15,
16, and 18. In contrast, genotyping of 14 additional mark-
ers (D8S264, D8S262, D8S1742, D8S277, D8S1706,
Febrile seizures
Afebrile seizures


















































































































































































































































































































































































































































































































Figure 3. Haplotype reconstruction for chromosome 8p23-p21 markers in family 12402. Microsatellite and VNTR markers are ordered from telomere to
centromere according to the University of California Santa Cruz genome map. The haplotype shared by members of family 12402 is surrounded by solid lines. The
haplotype shared by members of family 15173 is surrounded by dashed lines. Observed recombinations are indicated by arrows. Mb indicates megabase.
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D8S351,D8S503,D8S552,VNTR22TG,D8S602,D8S639,
D8S261,VNTR25CA, andD8S258) confirmed linkage on
chromosome 8p23-p21. Maximal pairwise LOD scores
were 3.00 at =0.0 for D8S351 and D8S550 calculated
using the affected only method (Table 2). The scores
recalculated with inclusion of all at-risk individuals yielded
pairwise LOD scores slightly below 3.00 (Table 2) be-
cause of incomplete penetrance. Under these condi-
tions, multipoint analysis with 15 markers generated a
maximal LOD score of 3.23 in the interval flanked by
D8S351 and VNTR25CA; the remaining genome was ex-
cluded (data not shown).
Haplotype reconstruction showed that all patients
shared a common haplotype encompassing markers
D8S351 (chromosome 8: 8 714 310-8 914 565) to
VNTR25CA (chromosome 8: 19 887 367-19 887 416)
(Figure 2). The boundaries of this interval were
defined by a recombination between markers D8S1706
and D8S351 in patient III:9 and a recombination
between markers VNTR25CA and D8S258 in patient
II:1. This genetic interval (D8S1706-D8S258) corre-
sponds to a 13-Mb (megabase) large region located on
chromosome 8p23.1-p21.3, according to the Univer-
sity of California Santa Cruz Genome Browser (http:
//genome.ucsc.edu/).
Genotyping of the Other Families
After establishing linkage at chromosome 8p23-p21 in fam-
ily 15173, the 4 smaller families with GEFS were ana-
lyzed. We obtained pairwise LOD scores less than −2 for
8p23-p21 markers in families 16923, 17516, and 15635
(data not shown) but positive pairwise LOD scores in fam-
ily 12402. The maximum pairwise LOD score was 2.03
for D8S262 calculated using the affected only method
(Table 2). Multipoint analysis gave maximal LOD scores
of 2.14 in the interval D8S262 to D8S1706 when all at-
risk individuals were included (data not shown). Haplo-
type reconstruction showed that the 7 affected patients and
the obligate carrier I:6 had a common haplotype of 12 Mb
(D8S262-D8S552), defined by a recombination between
markers D8S264 and D8S262 in patient I:4 and a recom-
Table 2. Pairwise LOD Scores for 15 Markers on Chromosome 8p23-p21 From Telomere (Top) to Centromere (Bottom)
for Family 15173 and Family 12402
Marker
LOD Scores
=0 =0.01 =0.05 =0.10 =0.20 =0.30 =0.40
AO AR AO AR AO AR AO AR AO AR AO AR AO AR
Family 15173
D8S262 −9.61 −3.56 −3.45 −2.85 −1.50 −1.70 −0.77 −1.09 −0.23 −0.53 −0.08 0.28 0.05 0.14
D8S1742 −3.83 0.30 −0.27 0.36 0.31 0.51 0.47 0.57 0.48 0.54 0.38 0.42 0.22 0.23
D8S277 1.16 1.16 1.14 1.14 1.03 1.03 0.90 0.90 0.63 0.62 0.35 0.34 0.10 0.10
D8S1706 −3.03 0.95 0.88 1.14 1.39 1.38 1.44 1.41 1.22 1.18 0.83 0.80 0.37 0.36
D8S351 3.00a 2.57 2.95 2.52 2.73 2.33 2.46 2.08 1.87 1.56 1.22 1.00 0.56 0.45
D8S503 2.06 1.68 2.02 1.64 1.82 1.48 1.58 1.27 1.07 0.84 0.56 0.40 0.15 0.09
D8S550 3.00a 2.57 2.95 2.52 2.73 2.33 2.46 2.08 1.87 1.56 1.22 1.00 0.56 0.45
D8S552 1.78 1.28 1.74 1.25 1.59 1.14 1.38 1.00 0.95 0.68 0.51 0.35 0.13 0.08
VNTR22TG 2.63 2.28 2.58 2.24 2.39 2.07 2.14 1.86 1.62 1.38 1.05 0.87 0.47 0.36
D8S549 2.37 2.16 2.32 2.12 2.15 1.97 1.92 1.78 1.44 1.34 0.93 0.87 0.42 0.39
D8S602 2.93 2.30 2.88 2.27 2.67 2.12 2.40 1.92 1.82 1.48 1.19 0.98 0.54 0.45
D8S639 2.67 2.44 2.62 2.40 2.43 2.23 2.18 2.00 1.65 1.51 1.08 0.97 0.50 0.44
D8S261 1.77 1.40 1.74 1.38 1.62 1.29 1.46 1.18 1.14 0.92 0.79 0.65 0.41 0.34
VNTR25CA 2.97 2.72 2.91 2.68 2.70 2.48 2.43 2.23 1.85 1.68 1.22 1.08 0.56 0.48
D8S258 −2.95 0.90 0.85 1.06 1.36 1.27 1.42 1.29 1.22 1.07 0.86 0.73 0.43 0.36
Family 12402
D8S262 2.03 1.71 1.99 1.68 1.83 1.55 1.62 1.38 1.17 0.99 0.68 0.56 0.20 0.16
D8S1742 1.44 1.39 1.41 1.36 1.27 1.24 1.10 1.08 0.74 0.74 0.39 0.39 0.11 0.11
D8S277 1.39 1.15 1.36 1.13 1.23 1.03 1.06 0.91 0.71 0.62 0.37 0.33 0.10 0.09
D8S1706 1.69 1.61 1.66 1.58 1.51 1.44 1.31 1.26 0.91 0.87 0.50 0.47 0.15 0.14
D8S351 1.05 0.43 1.02 0.42 0.90 0.38 0.75 0.33 0.47 0.22 0.23 0.12 0.06 0.03
D8S503 1.40 0.76 1.37 0.74 1.22 0.66 1.04 0.56 0.67 0.35 0.33 0.17 0.09 0.04
D8S550 1.41 0.72 1.37 0.70 1.22 0.62 1.04 0.52 0.67 0.32 0.33 0.16 0.09 0.04
D8S552 0.80 0.68 0.78 0.67 0.72 0.61 0.63 0.53 0.45 0.37 0.25 0.20 0.08 0.06
VNTR22TG −4.10 −0.17 −0.68 −0.07 −0.09 0.12 0.08 0.20 0.14 0.19 0.09 0.10 0.03 0.03
D8S549 0.81 0.69 0.79 0.68 0.71 0.60 0.61 0.51 0.40 0.34 0.21 0.17 0.06 0.05
D8S602 0.81 0.69 0.79 0.68 0.71 0.60 0.61 0.51 0.40 0.34 0.21 0.17 0.06 0.05
D8S639 −4.00 −0.17 −0.33 −0.05 0.24 0.18 0.37 0.27 0.34 0.26 0.20 0.15 0.06 0.04
D8S261 0.51 0.41 0.50 0.40 0.46 0.37 0.41 0.32 0.29 0.22 0.16 0.12 0.05 0.03
VNTR25CA 0.81 0.69 0.79 0.68 0.71 0.60 0.61 0.51 0.40 0.34 0.21 0.17 0.06 0.05
D8S258 0.81 0.47 0.78 0.45 0.69 0.39 0.57 0.31 0.33 0.16 0.14 0.05 0.03 0.01
Abbreviations: AO, “affected only” method; AR, all at-risk individuals; LOD, logarithm of odds.
aMaximum LOD scores.
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bination between markersD8S552 andVNTR22TG in pa-
tient II:2. This haplotype encompassed a region of 7.3 Mb
that overlapped with the haplotype segregating in family
15173, suggesting that both families are linked to the same
locus on chromosome 8p23-p21 (Figure 3). However, the




To confirm that FSs in family 12402 were caused by a mu-
tation in a gene located in this 8p23-p21 locus and that it
did not segregate with the disease by chance, we per-
formed a whole genome scan using 380 microsatellite mark-
ers. Calculation of pairwise LOD scores showed that 55 of
380 markers were not informative; they were excluded by
means of haplotype reconstruction. Two adjacent nonin-
formative markers, D16S3103 and D16S3046, were ex-
cluded after saturation of the interval with markers
D16S3062,D16S405,D16S3041,D16S3017, andD16S412.
In addition, positive pairwise LOD scores were obtained
for11of380markers (D1S2726,D4S1534,D5S422,D6S462,
D8S277,D13S171,D17S787,D19S902,D19S418,D19S226,
andD22S420). Areas on chromosomes 1, 4, 6, and 17 were
excluded by means of haplotype reconstruction. Addi-
tional microsatellite markers (D5S412,D13S260,D13S1493,
D13S1293, D13S1246, D19S879, D19S556, D19S545,
D19S892, D19S879, and D22S427) were further geno-
typed to exclude the regions on chromosomes 5, 13, 19,
and 22. Because the remaining genome was excluded, we




According to Ensembl (http://www.ensembl.org), the ge-
netic interval of interest spans 7.3 Mb and contains ap-
proximately 80 known genes. The region contains no ion
channel or neurotransmitter genes. We prioritized the
genes according to their patterns of expression in the brain
and putative functions and sequenced 6 candidate
genes—MTMR9, MTMR7, CTSB, SGCZ, SG223, and
ATP6V1B2—in patient II:4 of family 15173 and in pa-
tient I:8 of family 12402 (Table 3). Some sequence vari-
ants were identified in each gene, but they were already
mentioned in databases as polymorphisms or were found
in 100 matched French controls.
COMMENT
We recruited 5 French families with a phenotype com-
patible with GEFS. The disorder segregated as an au-
tosomal dominant trait with incomplete penetrance in
all families. Most patients in the 5 families experienced
simple FSs (93%) and some afebrile seizures (34%), mostly
GTCSs or absence seizures. None of the families were
linked to the previously reported GEFS and FS loci.
A 10-cM-density genomewide scan in the most infor-
mative family (15173) revealed a unique region with sig-
nificant maximum pairwise LOD scores of 3.00 and mul-
tipoint LOD scores of 3.23 on chromosome 8p23-p21,
which strongly suggests that we have identified a new lo-
cus for GEFS. Because all other regions of the genome
were excluded, we believe that the responsible gene is prob-
ably localized in this interval. Furthermore, when the 4
other families were then tested for linkage to this novel
locus, we obtained evidence of probable linkage in 1 fam-
ily (12402) to a region of 7.3 Mb that overlapped the lo-
cus on chromosome 8p23-p21 in family 15173. Al-
though a linkage in family 12402 might have been obtained
by chance, the absence of any other positive region is in
favor of a conclusive linkage. Furthermore, all affected fam-
ily members shared the same haplotype, and no pheno-
copies were identified. Although 4 unaffected individu-
als (including 2 obligate carriers) in family 15173 and 5
(including 2 obligate carriers) in family 12402 also car-
ried the haplotype associated with the disease, this illus-
trates an incomplete penetrance of GEFS associated with
8p23-p21. This would not be unusual because reduced pen-
etrance of 60% has previously been reported in families
with GEFS,12 and it was estimated to be 64% in a collec-
tion of families with FSs.20 The present data suggest that
this locus is involved in 2 of the 5 families tested, suggest-
ing that it might not be a rare locus.
We described in detail the clinical features of the 2
families, 15173 and 12402, linked to the new locus on
chromosome 8p23-p21. In family 15173, all affected in-
dividuals experienced FSs, and 3 of 11 also experienced
Table 3. Candidate Genes Explored in the 8p23-p21 Intervala
Gene Symbol
Position in Bases
at Chromosome 8 Protein Potential Role in Epilepsy
SG223 8 212 676-8 276 667 Tyrosine-protein kinase Homology with rat pragma of Rnd2, which is
involved in the migration of pyramidal neurons15
MTMR9 11 179 410-11 223 064 Myotubularin-related protein 9 Brain binding partner of MTMR7 16
CTSB 11 739 236-11 744 571 Cathepsin B Upregulated after seizures provoked by
hippocampal kindling17
SGCZ 13 991 744-15 140 163 Sarcoglycan zeta Abundant in the brain18
MTMR7 17 203 534-17 250 961 Myotubularin-related protein 7 Brain binding partner of MTMR9 16
ATP6V1B2 20 098 984-20 123 487 ATP synthase subunit B High levels of expression in the brain19
aThe MTMR7 and ATP6V1B2 genes are located outside of the common interval of both families but were initially screened because they were included in the
interval segregating in family 15173.
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afebrile seizures. Four patients reported the occurrence
of FSs after age 6 years and experienced many episodes
of FS, or a combination of FSs and afebrile seizures, which
were defined as “FS plus.”1 Family 12402 had 11 af-
fected members. Febrile seizures were present in 6 pa-
tients, complex in 2, and lasted until 8 years of age in 1
patient (I:8). The FSs recurred more than 5 times in half
of these patients, with more than 10 episodes in patient
I:8. In addition, 3 patients also developed afebrile sei-
zures: GTCSs in 1 and absence epilepsy in 2. Three pa-
tients had epilepsy with no history of FSs (partial epi-
lepsy in 2 and absences in the third). Frequent absences
have already been reported in other families with
GEFS.21,22 Both families corresponded to the descrip-
tion of the familial GEFS context.
In the literature, phenotype-genotype correlations have
been reported in families with GEFS. For example, the
proportion of patients with FS was higher in families
with SCN1Amutations than in families withGABRG2mu-
tations.23 In the present study, families with linkage to
the 8p23-p21 locus had a higher proportion of patients
with FS than did families without linkage (28% vs 7%).
Furthermore, there was a high rate of recurrence of FSs
in 53% of patients from families linked to chromosome
8p23-p21, whereas frequent recurrence was reported in
only 1 of 27 patients (4%) from families excluded for this
locus. Complex FSs were observed in only the 2 fami-
lies linked to chromosome 8p23-p21 (4 of 17 patients).
Afebrile seizures co-occurred with FSs in at least 1 pa-
tient per family except for family 15635. Because none
of the patients had FS in this family, it was considered
to be a family with epilepsy and FSs rather than typical
GEFS.
The new locus contains approximately 80 known
genes, none of which are known or predicted to encode
ion channels, neurotransmitter receptors, or proteins ho-
mologous to others involved in epilepsy. Twenty of the
genes encode defensins and were not considered as can-
didates for epilepsy. Thirty genes encode unknown pro-
teins. To identify the causative gene, we sequenced the
coding regions and flanking splicing sites of genes en-
coding proteins expressed in brain or with a putative role
in epilepsy (Table 3). So far, no causal mutations have
been identified in the coding regions of the following
genes: CTSB, SGCZ, SG223, MTMR9, MTMR7, and
ATP6V1B2. We hope that elucidation of the function of
the unknown proteins encoded by genes located in the
interval will provide new candidates to screen for FSs and
epilepsy. In parallel, we will search for rearrangements
that are reported to be frequent in the 8p23 region.24,25
Identification of additional families with GEFS linked
to the 8p23-p21 region will reinforce linkage to this new
locus, the sixth to be identified for this disorder. This
might also narrow the candidate interval and conse-
quently decrease the number of candidate genes to ex-
plore. So far, 3 genes have been implicated in GEFS:
SCN1A, SCN1B, and GABRG2. Except for leucine-rich
glioma inactivated 1 (LGI1) and EF-hand domain (C-
terminal) containing 1 (EFHC1), all other genes in-
volved in idiopathic monogenic epilepsies encode ion
channel or neurotransmitter receptor genes.26 It is, thus,
interesting that the novel locus reported herein does not
contain genes with functions similar to those already im-
plicated in epilepsy. Identification of the responsible gene
in 8p23-p21 might bring to light a new mechanism in-
volved in epileptogenesis.
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Announcement
Trial Registration Required. In concert with the Inter-
national Committee of Medical Journal Editors (ICMJE),
Archives of Neurology will require, as a condition of con-
sideration for publication, registration of all trials in a pub-
lic trials registry (such as http://ClinicalTrials.gov). Trials
must be registered at or before the onset of patient en-
rollment. This policy applies to any clinical trial start-
ing enrollment after July 1, 2005. For trials that began
enrollment before this date, registration will be re-
quired by September 13, 2005, before considering the
trial for publication. The trial registration number should
be supplied at the time of submission.
For details about this new policy, and for information
on how the ICMJE defines a clinical trial, see the edi-
torial by DeAngelis et al in the January issue of Archives
of Dermatology (2005;141:76-77). Also see the Instruc-
tions to Authors on our Web site: www.archneurol.com.
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